Evidence map›Paper›PMID 35887839›Full record

ArticleJournal of clinical medicine2022

Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients.

Dimitrios Balalis, Dimitrios Tsakogiannis, Eleni Kalogera, Stefania Kokkali, Elli Tripodaki, Alexandros Ardavanis, Dimitrios Manatakis, Dionysios Dimas, Nektarios Koufopoulos, Florentia Fostira and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Dimitrios BalalisDepartment of Surgical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece.
Dimitrios TsakogiannisResearch Center, Hellenic Anticancer Institute, 10680 Athens, Greece.ORCID 0000-0001-6835-8410
Eleni KalogeraResearch Center, Hellenic Anticancer Institute, 10680 Athens, Greece.
Stefania KokkaliDepartment of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-6531-3866
Elli TripodakiDepartment of Medical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece.
Alexandros ArdavanisDepartment of Medical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece.
Dimitrios ManatakisDepartment of Surgery, Athens Naval and Veterans Hospital, 11521 Athens, Greece.
Dionysios DimasBreast Unit, Psychikon Clinic, Athens Medical Center, 11525 Athens, Greece.
Nektarios KoufopoulosDepartment of Pathology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0001-9502-7916
Florentia FostiraMolecular Diagnostics Laboratory, Institute of Nuclear & Radiological Sciences and Technology, Energy & Safety (INRASTES), National Center for Scientific Research Demokritos, 15341 Athens, Greece.
Dimitrios KorkolisDepartment of Surgical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece.ORCID 0000-0003-0682-2374
Ioannis MisitzisBreast Unit, Psychikon Clinic, Athens Medical Center, 11525 Athens, Greece.
Nikolaos VassosMedical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany.ORCID 0000-0002-0580-5663
Chara SpiliopoulouDepartment of Forensic Medicine and Toxicology, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Dimitrios VlachodimitropoulosDepartment of Forensic Medicine and Toxicology, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Garyfalia BletsaResearch Center, Hellenic Anticancer Institute, 10680 Athens, Greece.
Nikolaos ArkadopoulosDepartment of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngiogenesis is a hallmark of breast cancer (BC) and is mediated by the vascular endothelial growth factor (VEGF) signaling axis. It is regulated by different proangiogenic factors, including platelet-derived growth factor-CC (PDGF-CC) and heparin-binding EGF-like growth factor (HB-EGF), as well as co-receptors, such as neuropilin-1, which could have prognostic implications in BC patients. PATIENTS AND

methodsWe assessed the serum levels of VEGF, HB-EGF, PDGF-CC and neuropilin-1 in 205 patients with early BC (invasive,

resultsVEGF serum levels were significantly higher in patients with invasive versus ductal carcinomas in situ. PDGF-CC serum concentrations varied among BC molecular subtypes. Furthermore, we observed a differential expression of most biomarkers between overweight/obese (body mass index (BMI) ≥ 25 kg/m

conclusionThe serum concentrations of angiogenic molecules differ among breast cancer molecular subtypes and are affected by the BMI and menopausal status, which could have possible clinical or prognostic implications.

Indexed as

angiogenesisbody mass indexbreast cancermenopausal statusmoleculessubtype

Identifiers

PMID35887839
PMCPMC9323050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.